Table 3.

Characteristics of cancer patients lacking seroconversion after vaccination.

Patients	Age	Gender	BMI (kg/m2)	Smoking	Steroid therapy	Comorbidities	ECOG PS	Primary tumour	Stage	Cancer therapy	Therapy response	Days from therapy administration to 2nd dose vaccination	Days from vaccine to sampling	Neutralising activity (%)
1	68	Female	37	Former	No	Cardiovascular, respiratory	1	NSCLC	Locally advanced	Cisplatin + vinorelbine	NE	19	17	33.39
2	64	Male	23	Active	No	No	2	Stomach	Metastatic	FOLFIRI	SD	7	22	5.50
3	65	Female	27	Never	No	No	0	Breast	Locally advanced	Doxorubicin + cyclophosphamide	PR	22	24	29.23
4	77	Male	26	Never	No	No	3	Pancreatic	Metastatic	FOLFOX	PD	10	25	31.38
5	76	Female	24	Active	No	No	3	NSCLC	Metastatic	Pembrolizumab	PR	15	27	6.00
6	73	Female	24	Never	No	Endocrine, autoimmune	1	Breast	Metastatic	Everolimus + exemestane	SD	0	29	32.74
7	60	Male	26	Active	No	No	2	Colorectal	Metastatic	FOLFOX + panitumumab	PR	14	29	0.00
8	75	Female	28	Never	No	Cardiovascular, diabetes, endocrine	2	Colorectal	Metastatic	FOLFOX + panitumumab	PR	6	29	NE
9	65	Female	34	Never	No	Cardiovascular	1	Colorectal	Metastatic	FOLFOX + bevacizumab	PR	5	30	24.9
10	53	Male	23	Former	Yes	No	2	NSCLC	Metastatic	Carboplatin + pemetrexed	PR	36	37	NE

Keys: BAU = binding arbitrary units; BMI = body mass index; ECOG = Eastern Cooperative Oncology Group; FOLFIRI = 5-fluorouracil, irinotecan, leucovorin; FOLFOX = 5-fluorouracil, leucovorin, oxaliplatin; mL = milliliter; NE = not evaluable; NSCLC = non-small cell lung cancer; PS = performance status; PD = progressive disease; PR = partial response; SD = stable disease.